uniQure (QURE) is advancing a pipeline of gene therapies that are developed internally and externally. It has a collaboration with Bristol-Myers Squibb (BMY) that’s targeted at cardiovascular disease. uniQure has also established a clinical proof of concept in hemophilia B and pre-clinical proof of concept in Huntington’s disease.
uniQure’s AMT-061 is being developed for the treatment of hemophilia B. In June, the company enrolled the first patient in its Phase 3 study of AMT-061 to study the drug’s safety and efficacy. uniQure plans to enroll 50 patients in the study.
uniQure’s AMT-130 is being developed for the treatment of Huntington’s disease. AMT-130 has received orphan drug designation in the United States and orphan medicinal product designation from the European Medicines Agency.
uniQure generated total licensing and collaboration revenues of $3.05 million in the second quarter of 2018 compared to $4.94 million in Q2 2017. For fiscal 2018 and fiscal 2019, uniQure is expected to generate revenues of $15.06 million and $14.88 million, respectively, compared to $13.11 million in fiscal 2017.
uniQure’s research and development expenses increased from $16.87 million in the second quarter of 2017 to $18.49 million in the second quarter of 2018. It’s selling, general, and administrative expenses increased from $5.41 million in the second quarter of 2017 to $5.89 million in the second quarter of 2018.
We’ll take a look at uniQure’s valuation metrics in the next part.